SEARCH

SEARCH BY CITATION

References

  • 1
    Aguayo, A., Kantarjian, H., Talpaz, M., Estey, E., Koller, C., Estrov, Z., Obrien, S., Keating, M., Barlogie, B., Albitar, M. (1998) Increased angiogenesis in chronic myeloid leukemia and myelodysplastic syndromes (Abstract). Blood, 92 (suppl. 1), p. 607a.
  • 2
    Anandappa, S.Y., Winstanley, J.H.R., Leinster, S., Green, B., Rudland, P.S., Barraclough, R. (1994) Comparative expression of fibroblast growth factor messenger RNAs in benign and malignant breast disease. British Journal of Cancer, 69, 772 776.
  • 3
    Andrade, S.P., Fan, T.P., Lewis, G.P. (1987) Quantitative in vivo studies on angiogenesis in a rat sponge model. British Journal of Experimental Pathology, 68, 755 766.
  • 4
    Arap, W., Pasqualini, R., Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279, 377 380.
  • 5
    Arbiser, J.L., Moses, M.A., Fernandez, C.A., Ghiso, N., Cao, Y.H., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., Byers, H.R., Folkman, J. (1997) Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proceedings of the National Academy of Sciences of the United States of America, 94, 861 866.
  • 6
    Arora, N., Masood, R., Zheng, T., Cai, J., Smith, D.L., Gill, P.S. (1999) Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Research, 59, 183 188.
  • 7
    Banks, R.E., Forbes, M.A., Kinsey, S.E., Stanley, A., Ingham, E., Walters, C., Selby, P.J. (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. British Journal of Cancer, 77, 956 964.
  • 8
    Bellamy, W.T., Richter, L., Frutiger, Y., Grogan, T.M. (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Research, 59, 728 733.
  • 9
    Ben-Av, P., Crofford, L.J., Wilder, R.L., Hla, T. (1995) Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Letters, 372, 83 87.
  • 10
    Benjamin, L.E., Golijanin, D., Itin, A., Pode, D., Keshet, E. (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. Journal of Clinical Investigation, 103, 159 165.
  • 11
    Bergers, G., Javaherian, K., Lo, K.M., Folkman, J., Hanahan, D. (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, 284, 808 812.
  • 12
    Bikfalvi, A. & Han, Z.C. (1994) Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia, 8, 523 529.
  • 13
    Boehm, T., Folkman, J., Browder, T., O'reilly, M.S. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390, 404 407.
  • 14
    Boehm, T., O'reilly, M.S., Keough, K., Shiloach, J., Shapiro, R., Folkman, J. (1998) Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochemical and Biophysical Research Communications, 252, 190 194.
  • 15
    Borgstrom, P., Bourdon, M.A., Hillan, K.J., Sriramarao, P., Ferrara, N. (1998) Neutralizing antivascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate, 35, 1 10.
  • 16
    Borset, M., HjorthHansen, H., Seidel, C., Sundan, A., Waage, A. (1996) Hepatocyte growth factor and its receptor c-Met in multiple myeloma. Blood, 88, 3998 4004.
  • 17
    Borset, M., Seidel, C., HjorthHansen, H., Waage, A., Sundan, A. (1999) The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leukemia and Lymphoma, 32, 249 256.
  • 18
    Boylan, M., Van Den Berg, H.W., Lynch, M. (1998) The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen. Annals of Oncology, 9, 205 211.
  • 19
    Braddock, P.S., Hu, D.E., Fan, T.P.D., Stratford, I.J., Harris, A.L., Bicknell, R. (1994) A structure–activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. British Journal of Cancer, 69, 890 898.
  • 20
    Brooks, P.C., Montgomery, A.M.P., Rosenfeld, M., Reisfeld, R.A., Hu, T.H., Klier, G., Cheresh, D.A. (1994) Integrin αv3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79, 1157 1164.
  • 21
    Brooks, P.C., Silletti, S., Von Schalscha, T.L., Friedlander, M., Cheresh, D.A. (1998) Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell, 92, 391 400.
  • 22
    Brown, L.F., Berse, B., Jackman, R.W., Tognazzi, K., Guidi, A.J., Dvorak, H.F., Senger, D.R., Connolly, J.L., Schnitt, S.J. (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Pathology, 26, 86 91.
  • 23
    Camussi, G., Montrucchio, G., Lupia, E., De Martino, A., Perona, L., Arese, M., Vercellone, A., Toniolo, A., Bussolino, F. (1995) Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. Journal of Immunology, 154, 6492 6501.
  • 24
    Carmeliet, P., Dor, Y., Herbert, J.M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C.J., Ratcliffe, P., Moons, L., Jain, R.K., Collen, D., Keshert, E. (1998) Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 394, 485 490.
  • 25
    Carmeliet, P., Mackman, N., Moons, L., Luther, T., Gressens, P., VanVlaenderen, I., Demunck, H., Kasper, M., Breier, G., Evrard, P., Muller, M., Risau, W., Edgington, T., Collen, D. (1996) Role of tissue factor in embryonic blood vessel development. Nature, 383, 73 75.
  • 26
    Cheresh, D.A. (1998) Death to a blood vessel, death to a tumor. Nature Medicine, 4, 395 396.
  • 27
    Ciardiello, F., Damiano, V., Bianco, R., Bianco, C., De Fontanini, G., Laurentiis, M., DePlacido, S., Mendelsohn, J., Bianco, A.R., Tortora, G. (1996) Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. Journal of the National Cancer Institute, 88, 1770 1776.
  • 28
    Clapp, C., Martial, J.A., Guzman, R.C., Rentier-Delrue, F., Weiner, R.I. (1993) The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology, 133, 1292 1299.
  • 29
    Cohen, J. (1999) Cancer therapy — behind the headlines of endostatin's ups and downs. Science, 283, 1250 1251.
  • 30
    Cox, A.D. & Der, C.J. (1997) Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochimica et Biophysica Acta Reviews on Cancer, 1333, F51 F71.
  • 31
    Dachs, G.U., Patterson, A.V., Firth, J.D., Ratcliffe, P.J., Townsend, K.M.S., Stratford, I.J., Harris, A.L. (1997) Targeting gene expression to hypoxic tumor cells. Nature Medicine, 3, 515 520.
  • 32
    D'amato, R.J., Loughnan, M.S., Flynn, E., Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 91, 4082 4085.
  • 33
    Dameron, K.M., Volpert, O.V., Tainsky, M.A., Bouck, N. (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science, 265, 1582 1584.
  • 34
    Darland, D.C. & D'amore, P.A. (1999) Blood vessel maturation: vascular development comes of age. Journal of Clinical Investigation, 103, 157 158.
  • 35
    Davis, S., Aldrich, T.H., Jones, P.F., Acheson, A., Compton, D.L., Jain, V., Ryan, T.E., Bruno, J., Radziejewski, C., Maisonpierre, P.C., Yancopoulos, G.D. (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell, 87, 1161 1169.
  • 36
    Dhanabal, M., Ramchandran, R., Waterman, M.J.F., Lu, H., Knebelmann, B., Segal, M., Sukhatme, V.P. (1999) Endostatin induces endothelial cell apoptosis. Journal of Biological Chemistry, 274, 11721 11726.
  • 37
    Dickinson, A.J., Fox, S.B., Persad, R.A., Hollyer, J., Sibley, G.N.A., Harris, A.L. (1994) Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. British Journal of Urology, 74, 762 766.
  • 38
    Dirix, L.Y., Vermeulen, P.B., Pawinski, A., Prove, A., Benoy, I., De Pooter, C., Martin, M., Van Oosterom, A.T. (1997) Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. British Journal of Cancer, 76, 238 243.
  • 39
    Ezekowitz, A., Mulliken, J., Folkman, J. (1991) Interferon alpha therapy of hemangiomas in newborns and infants. British Journal of Haematology, 79, 67 68.
  • 40
    Ferrara, N. & Davis-Smyth, T. (1997) The biology of vascular endothelial growth factor. Endocrine Reviews, 18, 4 25.
  • 41
    Fiedler, W., Graeven, U., Ergun, S., Verago, S., Kilic, N., Stockschlader, M., Hossfeld, D.K. (1997) Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 89, 1870 1875.
  • 42
    Figg, W.D., Raje, S., Bauer, K.S., Tompkins, A., Venzon, D., Bergan, R., Chen, A., Hamilton, M., Pluda, J., Reed, E. (1999) Pharmacokinetics of thalidomide in an elderly prostate cancer population. Journal of Pharmaceutical Sciences, 88, 121 125.
  • 43
    Folkman, J. (1974) Tumor angiogenesis. Advances in Cancer Research, 19, 331 358.
  • 44
    Folkman, J. (1990) What is the evidence that tumors are angiogenesis dependent. Journal of the National Cancer Institute, 82, 4 6.
  • 45
    Folkman, J. & Klagsbrun, M. (1987) Angiogenic factors. Science, 235, 442 447.
  • 46
    Fotsis, T., Zhang, Y.M., Pepper, M.S., Adlercreutz, H., Montesano, R., Nawroth, P.P., Schweigerer, L. (1994) The endogenous estrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature, 368, 237 239.
  • 47
    Fox, S.B., Gatter, K.C., Harris, A.L. (1996) Tumour angiogenesis. Journal of Pathology, 179, 232 237.
  • 48
    Fox, S.B. & Harris, A.L. (1997) Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Investigational New Drugs, 15, 15 28.
  • 49
    Fraterschroder, M., Risau, W., Hallmann, R., Gautschi, P., Bohlen, P. (1987) Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proceedings of the National Academy of Sciences of the United States of America, 84, 5277 5281.
  • 50
    Furlong, R.A., Takehara, T., Taylor, W.G., Nakamura, T., Rubin, J.S. (1991) Comparison of biological and immunochemical properties indicates that scatter factor and hepatocyte growth factor are indistinguishable. Journal of Cell Science, 100, 173 177.
  • 51
    Giatromanolaki, A., Koukourakis, M., Obyrne, K., Fox, S., Whitehouse, R., Talbot, D.C., Harris, A.L., Gatter, K.C. (1996) Prognostic value of angiogenesis in operable non-small cell lung cancer. Journal of Pathology, 179, 80 88.
  • 52
    Gimbrone, Jr, M.A., Cotran, R.S., Leapman, S.B., Folkman, J. (1974) Tumor growth and neovascularization: an experimental model using the rabbit cornea. Journal of the National Cancer Institute, 52, 413 427.
  • 53
    Goldman, C.K., Kendall, R.L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G.Y., Siegal, G.P., Mao, X.Z., Bett, A.J., Huckle, W.R., Thomas, K.A., Curiel, D.T. (1998) Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proceedings of the National Academy of Sciences of the United States of America, 95, 8795 8800.
  • 54
    Good, D.J., Polverini, P.J., Rastinejad, F., Le Beau, M.M., Lemons, R.S., Frazier, W.A., Bouck, N.P. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proceedings of the National Academy of Sciences of the United States of America, 87, 6624 6628.
  • 55
    Gore, M., A'hern, R., Stankiewicz, M., Slevin, M. (1996) Tumour marker levels during marimastat therapy (Letter). Lancet, 348, 263.
  • 56
    Gu, Y.Z., Moran, S.M., Hogenesch, J.B., Wartman, L., Bradfield, C.A. (1998) Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF-3α. Gene Expression, 7, 205 213.
  • 57
    Guillemin, K. & Krasnow, M.A. (1997) The hypoxic response: Huffing and HIFing. Cell, 89, 9 12.
  • 58
    Harris, A.L. (1997) Clinical trials of anti-vascular agent group B streptococcus toxin . Angiogenesis, 1, 36 37.
  • 59
    Hasinoff, B.B., Hellmann, K., Herman, E.H., Ferrans, V.J. (1998) Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Current Medicinal Chemistry, 5, 1 28.
  • 60
    Hellerqvist, C.G., Thurman, G.B., Page, D.L., Wang, Y.F., Russell, B.A., Montgomery, C.A., Sundell, H.W. (1993) Antitumor effects of GBS toxin: a polysaccharide exotoxin from group B beta-hemolytic streptococcus. Journal of Cancer Research and Clinical Oncology, 120, 63 70.
  • 61
    Hildenbrand, R., Dilger, I., Horlin, A., Stutte, H.J. (1995) Urokinase plasminogen-activator induces angiogenesis and tumor vessel invasion in breast cancer. Pathology Research and Practice, 191, 403 409.
  • 62
    Hirschi, K.K. & D'amore, P.A. (1996) Pericytes in the microvasculature. Cardiovascular Research, 32, 687 698.
  • 63
    Hjorth-Hansen, H., Seidel, C., Lamvik, J., Borset, M., Sundan, A., Waage, A. (1999) Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia. European Journal of Haematology, 62, 129 134.
  • 64
    Hockel, M., Schlenger, K., Hockel, S., Aral, B., Schaffer, U., Vaupel, P. (1998) Tumor hypoxia in pelvic recurrences of cervical cancer. International Journal of Cancer, 79, 365 369.
  • 65
    Horak, E.R., Leek, R., Klenk, N., LeJeune, S., Smith, K., Stuart, N., Greenall, M., Stepniewska, K., Harris, A.L. (1992) Angiogenesis, assessed by platelet endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet, 340, 1120 1124.
  • 66
    Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., Folkman, J. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature, 348, 555 557.
  • 67
    Iurlaro, M., Vacca, A., Minischetti, M., Ribatti, D., Sardanelli, A., Giacchetta, F., Dammacco, F. (1998) Antiangiogenesis by cyclosporin. Experimental Hematology, 26, 1215 1222.
  • 68
    Jiang, B.H., Agani, F., Passaniti, A., Semenza, G.L. (1997) V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Research, 57, 5328 5335.
  • 69
    Jones, J.L. & Walker, R.A. (1997) Control of matrix metalloproteinase activity in cancer. Journal of Pathology, 183, 377 379.
  • 70
    Kaban, L.B., Mulliken, J.B., Ezekowitz, R.A., Ebb, D., Smith, P.S., Folkman, J. (1999) Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics, 103, 1145 1149.
  • 71
    Kehinde, E.O., Terry, T.R., Mistry, N., Horsburgh, T., Sandhu, D.P., Bell, P.R.F. (1995) UK studies on suramin therapy in hormone resistant prostate cancer. Cancer Surveys, 23, 217 229.
  • 72
    Kenyon, B.M., Browne, F., Damato, R.J. (1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Experimental Eye Research, 64, 971 978.
  • 73
    Kerbel, R.S., Viloria-Petit, A., Okada, F., Rak, J. (1998) Establishing a link between oncogenes and tumor angiogenesis. Molecular Medicine, 4, 286 295.
  • 74
    Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., Ferrara, N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature, 362, 841 844.
  • 75
    Kini, A.R., Peterson, L.C., Kay, N.E. (1998) Evidence for abnormal angiogenesis in the bone marrow of patients with B-cell chronic lymphocytic leukemia (CLL). Blood, 92, 2947.
  • 76
    Kini, A.R., Tallman, M.S., Peterson, L.C. (1999) Abnormal angiogenesis in the bone marrow of patients with hairy cell leukemia (HCL). Laboratory Investigation, 79, 819.
  • 77
    Klauber, N., Rohan, R.M., Flynn, E., Damato, R.J. (1997a) Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nature Medicine, 3, 443 446.
  • 78
    Klauber, N., Parangi, S., Flynn, E., Hamel, E., Damato, R.J. (1997b) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Research, 57, 81 86.
  • 79
    Kohn, E.C., Reed, E., Sarosy, G., Christian, M., Link, C.J., Cole, K., Figg, W.D., Davis, P.A., Jacob, J., Goldspiel, B., Liotta, L.A. (1996) Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Research, 56, 569 573.
  • 80
    Kong, H.-L. & Crystal, R.G. (1998) Gene therapy strategies for tumor antiangiogenesis. Journal of the National Cancer Institute, 90, 273 286.
  • 81
    Kudelka, A.P., Verschraegen, C.F., Loyer, E. (1998) Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. New England Journal of Medicine, 338, 991 992.
  • 82
    Lin, P.N., Buxton, J.A., Acheson, A., Radziejewski, C., Maisonpierre, P.C., Yancopoulos, G.D., Channon, K.M., Hale, L.P., Dewhirst, M.W., George, S.E., Peters, K.G. (1998) Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proceedings of the National Academy of Sciences of the United States of America, 95, 8829 8834.
  • 83
    Maione, T.E., Gray, G.S., Petro, J., Hunt, A.J., Donner, A.L., Bauer, S.I., Carson, H.F., Sharpe, R.J. (1990) Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science, 247, 77 79.
  • 84
    Maisonpierre, P.C., Suri, C., Jones, P.F., Bartunkova, S., Wiegand, S., Radziejewski, C., Compton, D., McClain, J., Aldrich, T.H., Papadopoulos, N., Daly, T.J., Davis, S., Sato, T.N., Yancopoulos, G.D. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 277, 55 60.
  • 85
    Marshall, J.L., Wellstein, A., Rae, J., DeLap, R.J., Phipps, K., Hanfelt, J., Yunmbam, M.K., Sun, J.X., Duchin, K.L., Hawkins, M.J. (1997) Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer. Clinical Cancer Research, 3, 2347 2354.
  • 86
    Mauceri, H.J., Hanna, N.N., Beckett, M.A., Gorski, D.H., Staba, M.-J., Stellato, K.A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G.A., Sukhatme, V.P., Kufe, D.W., Weichselbaum, R.R. (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature, 394, 287 291.
  • 87
    Maxwell, P.H., Dachs, G.U., Gleadle, J.M., Nicholls, L.G., Harris, A.L., Stratford, I.J., Hankinson, O., Pugh, C.W., Ratcliffe, P.J. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 94, 8104 8109.
  • 88
    Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., Ratcliffe, P.J. (1999) The tumour suppressor protein VHL targets hypoxia inducible factors for oxygen dependent proteolysis. Nature, 399, 271 275.
  • 89
    Millauer, B., Longhi, M.P., Plate, K.H., Shawver, L.K., Risau, W., Ullrich, A., Strawn, L.M. (1996) Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Research, 56, 1615 1620.
  • 90
    Min, H.Y., Doyle, L.V., Vitt, C.R., Zandonella, C.L., Stratton-Thomas, J.R., Shuman, M.A., Rosenberg, S. (1996) Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Research, 56, 2428 2433.
  • 91
    Mitchell, C.A., Davies, M.J., Grounds, M.D., McGeachie, J.K., Crawford, G.J., Hong, Y., Chirila, T.V. (1996) Enhancement of neovascularization in regenerating skeletal muscle by the sustained release of erucamide from a polymer matrix. Journal of Biomaterials Applications, 10, 230 249.
  • 92
    Moehler, T.M., Hawighorst, H., Max, R., Hegenbart, U., Knopp, M.V., Van Kaick, G., Ho, A.D., Goldschmidt, H. (1998) Monitoring of vascularity and blood vessel permeability in bone lesions of multiple myeloma by magnetic resonance imaging. Blood, 92, 405.
  • 93
    Moenner, M., Gusse, M., Hatzi, E., Badet, J. (1994) The widespread expression of angiogenin in different human cells suggests a biological function not only related to angiogenesis. European Journal of Biochemistry, 226, 483 490.
  • 94
    Moghaddam, A., Zhang, H.T., Fan, T.P.D., Hu, D.E., Lees, V.C., Turley, H., Fox, S.B., Gatter, K.C., Harris, A.L., Bicknell, R. (1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 92, 998 1002.
  • 95
    Montesano, R., Matsumoto, K., Nakamura, T., Orci, L. (1991) Identification of a fibroblast derived epithelial morphogen as hepatocyte growth factor. Cell, 67, 901 908.
  • 96
    Motzer, R.J., Schwartz, L., Law, T.M., Murphy, B.A., Hoffman, A.D., Albino, A.P., Vlamis, V., Nanus, D.M. (1995) Interferon alfa-2α and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. Journal of Clinical Oncology, 13, 1950 1957.
  • 97
    Munshi, N., Wilson, C.S., Penn, J., Epstein, J., Singhal, S., Hough, A., Sanderson, R., Desikan, R., Siegel, D., Mehta, J., Barlogie, B. (1998) Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density (MVD) in bone marrow biopsies. Blood, 92, 400.
  • 98
    Ohlms, L.A., McGill, T.J.I., Jones, D.T., Healy, G.B. (1994) Interferon alfa-2a therapy for airway hemangiomas. Annals of Otology Rhinology and Laryngology, 103, 1 8.
  • 99
    O'reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn, E., Birkhead, J.R., Olsen, B.R., Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277 285.
  • 100
    O'reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y.H., Sage, E.H., Folkman, J. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315 328.
  • 101
    Perez-Atayde, A.R., Sallan, S.E., Tedrow, U., Connors, S., Allred, E., Folkman, J. (1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. American Journal of Pathology, 150, 815 821.
  • 102
    Pike, S.E., Yao, L., Jones, K.D., Cherney, B., Appella, E., Sakaguchi, K., Nakhasi, H., Teruya-Feldstein, J., Wirth, P., Gupta, G., Tosato, G. (1998) Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. Journal of Experimental Medicine, 188, 2349 2356.
  • 103
    Rajkumar, S.V., Fonseca, R., Witzig, T.E., Gertz, M.A., Greipp, P.R. (1999) Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia, 13, 469 472.
  • 104
    Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., Kerbel, R.S. (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Research, 55, 4575 4580.
  • 105
    Raleigh, J.A., Calkins-Adams, D.P., Rinker, L.H., Ballenger, C.A., Weissler, M.C., Fowler, W.C., Novotny, D.B., Varia, M.A. (1998) Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Research, 58, 3765 3768.
  • 106
    Relf, M., LeJeune, S., Scott, P.A.E., Fox, S., Smith, K., Leek, R., Moghaddam, A., Whitehouse, R., Bicknell, R., Harris, A.L. (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Research, 57, 963 969.
  • 107
    Ribatti, D., Nico, B., Vacca, A., Marzullo, A., Calvi, N., Roncali, L., Dammacco, F. (1998) Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas? British Journal of Cancer, 77, 1900 1906.
  • 108
    Ribatti, D., Vacca, A., Nico, B., Fanelli, M., Roncali, L., Dammacco, F. (1996) Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. European Journal of Haematology, 56, 45 53.
  • 109
    Ribatti, D., Vacca, A., Nico, B., Quondamatteo, F., Ria, R., Minischetti, M., Marzullo, A., Herken, R., Roncali, L., Dammacco, F. (1999) Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. British Journal of Cancer, 79, 451 455.
  • 110
    Risau, W. (1997) Mechanisms of angiogenesis. Nature, 386, 671 674.
  • 111
    Roberts, A.B., Sporn, M.B., Assoian, R.K., Smith, J.M., Roche, N.S., Wakefield, L.M., Heine, U.I., Liotta, L.A., Falanga, V., Kehrl, J.H., Fauci, A.S. (1986) Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proceedings of the National Academy of Sciences of the United States of America, 83, 4167 4171.
  • 112
    Ryan, H.E., Lo, J., Johnson, R.S. (1998) HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO Journal, 17, 3005 3015.
  • 113
    Sage, E.H. (1997) Pieces of eight: bioactive fragments of extracellular proteins as regulators of angiogenesis. Trends in Cell Biology, 7, 182 186.
  • 114
    Salceda, S. & Caro, J. (1997) Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox induced changes. Journal of Biological Chemistry, 272, 22642 22647.
  • 115
    Salgado, R., Vermeulen, P.B., Benoy, I., Weytjens, R., Huget, P., Van Marck, E., Dirix, L.Y. (1999) Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. British Journal of Cancer, 80, 892 897.
  • 116
    Salven, P., Teerenhovi, L., Joensuu, H. (1997) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood, 90, 3167 3172.
  • 117
    Selinsky, B.S., Zhou, Z., Fojtik, K.G., Jones, S.R., Dollahon, N.R., Shinnar, A.E. (1998) The aminosterol antibiotic squalamine permeabilizes large unilamellar phospholipid vesicles. Biochimica et Biophysica Acta Biomembranes, 1370, 218 234.
  • 118
    Semenza, G.L. & Wang, G.L. (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Molecular and Cellular Biology, 12, 5447 5454.
  • 119
    Shalaby, F., Rossant, J., Yamaguchi, T.P., Gertsenstein, M., Wu, X.-F., Breitman, M.L., Schuh, A.C. (1995) Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Nature, 376, 62 66.
  • 120
    Shami, P.J., Hussong, J.W., Rodgers, G.M. (1998) Evidence of increased angiogenesis in the bone marrow of patients with acute nonlymphocytic leukemia. Blood, 92, 2105.
  • 121
    Siemeister, G., Weindel, K., Mohrs, K., Barleon, B., Martiny-Baron, G., Marme, D. (1996) Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Research, 56, 2299 2301.
  • 122
    Silva, H.T. & Morris, R.E. (1997) Leflunomide and malononitrilamides. American Journal of Medical Sciences, 313, 289 301.
  • 123
    Sin, N., Meng, L.H., Wang, M.Q.W., Wen, J.J., Bornmann, W.G., Crews, C.M. (1997) The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proceedings of the National Academy of Sciences of the United States of America, 94, 6099 6103.
  • 124
    Singh, R.K., Gutman, M., Bucana, C.D., Sanchez, R., Llansa, N., Fidler, I.J. (1995) Interferon alpha and interferon beta down regulate the expression of basic fibroblast growth factor in human carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 92, 4562 4566.
  • 125
    Singhal, S., Mehta, J., Eddlemon, P., Gray, P., Cromer, J., Desikan, R., Ayers, D., Siegel, D., Munshi, N., Anaissie, E., Kantarjian, H., Zeldis, J., Barlogie, B. (1998) Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM). Blood, 92, 1306.
  • 126
    Spencer, C.M. & Faulds, D. (1994) Paclitaxel a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs, 48, 794 847.
  • 127
    Stewart, R., Nelson, J., Wilson, D.J. (1989) Epidermal growth factor promotes chick embryonicarcinogenesis. Cell Biology International Reports, 13, 957 965.
  • 128
    Suri, C., Jones, P.F., Patan, S., Bartunkova, S., Maisonpierre, P.C., Davis, S., Sato, T.N., Yancopoulos, G.D. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell, 87, 1171 1180.
  • 129
    Takahashi, Y., Kitadai, Y., Bucana, C.D., Cleary, K.R., Ellis, L.M. (1995) Expression of vascular endothelial growth factor and its receptor, Kdr, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Research, 55, 3964 3968.
  • 130
    Takakura, N., Huang, X.L., Dumont, D., Yancopoulos, G.D., Suda, T. (1998) TIE2–mediated interaction between hematopoietic cells and endothelial cells. Experimental Hematology, 26, 434.
  • 131
    Tian, H., McKnight, S.L., Russell, D.W. (1997) Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes and Development, 11, 72 82.
  • 132
    Toi, M., Harris, A.L., Bicknell, R. (1991) Interleukin-4 is a potent mitogen for capillary endothelium. Biochemical and Biophysical Research Communications, 174, 1287 1293.
  • 133
    Vacca, A., Diloreto, M., Ribatti, D., Distefano, R., Gadaleta-Caldarola, G., Iodice, G., Caloro, D., Dammacco, F. (1995a) Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. American Journal of Hematology, 50, 9 14.
  • 134
    Vacca, A., Ribatti, D., Iurlaro, M., Albini, A., Minischetti, M., Bussolino, F., Pellegrino, A., Ria, R., Rusnati, M., Presta, M., Vincenti, V., Persico, M.G., Dammacco, F. (1998) Human lymphoblastoid cells produce extracellular matrix degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. International Journal of Clinical and Laboratory Research, 28, 55 68.
  • 135
    Vacca, A., Ribatti, D., Roncali, L., Dammacco, F. (1995b) Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leukemia and Lymphoma, 20, 27 41.
  • 136
    Vacca, A., Ribatti, D., Ruco, L., Giacchetta, F., Nico, B., Quondamatteo, F., Ria, R., Iurlaro, M., Dammacco, F. (1999) Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. British Journal of Cancer, 79, 965 970.
  • 137
    Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F., Dammacco, F. (1994) Bone marrow angiogenesis and progression in multiple myeloma. British Journal of Haematology, 87, 503 508.
  • 138
    Voest, E.E., Kenyon, B.B., Oreilly, M.S., Truitt, G., Damato, R.J., Folkman, J. (1995) Inhibition of angiogenesis in vivo by interleukin-12. Journal of the National Cancer Institute, 87, 581 586.
  • 139
    Walther, M.M., Figg, W.D., Linehan, W.M. (1996) Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. World Journal of Urology, 14, S8 S11.
  • 140
    Wamil, B.D., Thurman, G.B., Sundell, H.W., DeVore, R.F., Wakefield, G., Johnson, D.H., Wang, Y.F., Hellerqvist, C.G. (1997) Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial. Journal of Cancer Research and Clinical Oncology, 123, 173 179.
  • 141
    Weidner, N., Semple, J.P., Welch, W.R., Folkman, J. (1991) Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. New England Journal of Medicine, 324, 1 8.
  • 142
    Wenger, R.H. & Gassmann, M. (1997) Oxygen(es) and the hypoxia inducible factor-1. Biological Chemistry, 378, 609 616.
  • 143
    Westermann, A.M., Dubbelman, R., Moolenaar, W.H., Beijnen, J., Rodenhuis, S. (1997) Successful intraperitoneal suramin treatment of peritoneal mesothelioma. Annals of Oncology, 8, 801 802.
  • 144
    Wiesener, M.S., Turley, H., Allen, W.E., Willam, C., Eckardt, K.U., Talks, K.L., Wood, S.M., Gatter, K.C., Harris, A.L., Pugh, C.W., Ratcliffe, P.J., Maxwell, P.H. (1998) Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1 α. Blood, 92, 2260 2268.
  • 145
    Wojtowicz-Praga, S.M., Dickson, R.B., Hawkins, M.J. (1997) Matrix metalloproteinase inhibitors. Investigational New Drugs, 15, 61 75.
  • 146
    Yaccoby, S., Barlogie, B., Epstein, J. (1998) Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood, 92, 2908 2913.
  • 147
    Yao, L., Sgadari, C., Furuke, K., Bloom, E.T., Teruya-Feldstein, J., Tosato, G. (1999) Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood, 93, 1612 1621.
  • 148
    Zetter, B.R. (1998) Angiogenesis and tumor metastasis. Annual Review of Medicine, 49, 407 424.
  • 149
    Zhang, H.T. & Harris, A.L. (1998) Anti-angiogenic therapies in cancer clinical trials. Expert Opinion Investigational Drugs, 7, 1629 1655.
  • 150
    Ziche, M., Maglione, D., Ribatti, D., Morbidelli, L., Lago, C.T., Battisti, M., Paoletti, I., Barra, A., Tucci, M., Parise, G., Vincenti, V., Granger, H.J., Viglietto, G., Persico, M.G. (1997a) Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Laboratory Investigation, 76, 517 531.
  • 151
    Ziche, M., Morbidelli, L., Choudhuri, R., Zhang, H.T., Donnini, S., Granger, H.J., Bicknell, R. (1997b) Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. Journal of Clinical Investigation, 99, 2625 2634.